NCOA2 and prostate carcinoma: AR co-activators such as SRC-1, SRC-3, TIF-2 [53], [54] which could enhance the transcriptional activity of AR and contribute to the sensitization of AR to low levels of androgen concentrations are also elevated in prostate cancer.